Invivyd Inc.

IVVD.US
Healthcare · Biotechnology
0.59
-0.02 (-2.72%)
USD · NASDAQ

Company Information

Company Name
Invivyd Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00534A1025
CIK: 0001832038
CUSIP: 00534A102
Currency: USD
Full Time Employees: 122
Phone: 781 819 0080
Fiscal Year End: December
IPO Date: Aug 06, 2021
Description:

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

Address:

209 Church Street, New Haven, CT, United States, 06510

People

Directors & Officers

Name Title Year Born
Mr. William E. Duke Jr., M.B.A. CFO, Principal Accounting Officer & Principal Executive Officer 1972
Ms. Jill Andersen J.D. Chief Legal Officer & Corporate Secretary 1973
Mr. Timothy Lee Chief Commercial Officer 1974
Dr. Robert D. Allen Ph.D. Chief Scientific Officer 1970
Ms. Kristie Coneys Kuhl J.D. Chief Communications Officer NA
Ms. Julie Green M.B.A. Chief Human Resources Officer 1976
Ms. Rachael Gerlach Ph.D. Senior Vice President of Regulatory Affairs NA
Ms. Katie Falzone CPA Senior Vice President of Finance NA
Dr. Michael J. Mina M.D., Ph.D. Chief Medical Officer 1984

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 18, 2026 Julie Green N/A Sale 20.96K $1.58 $33.12K
Feb 18, 2026 Robert D Allen III N/A Sale 19.39K $1.58 $30.64K
Feb 18, 2026 Timothy Edward Lee N/A Sale 20.96K $1.58 $33.12K
Feb 18, 2026 William E Duke N/A Sale 20.96K $1.58 $33.12K
Feb 18, 2026 Jill Andersen N/A Sale 34.94K $1.58 $55.20K
Feb 17, 2026 Jill Andersen N/A Sale 32.77K $1.54 $50.47K
Feb 17, 2026 Julie Green N/A Sale 19.66K $1.54 $30.28K
Feb 17, 2026 Robert D Allen III N/A Sale 18.19K $1.54 $28.01K
Feb 17, 2026 Timothy Edward Lee N/A Sale 19.66K $1.54 $30.28K
Feb 17, 2026 William E Duke N/A Sale 19.66K $1.54 $30.28K
Nov 19, 2025 Kevin F Mclaughlin N/A Purchase 50.00K $2.50 $125.00K
Aug 19, 2025 Jill Andersen N/A Sale 49.40K $0.57 $28.16K
Aug 19, 2025 Julie Green N/A Sale 29.64K $0.57 $16.90K
Aug 19, 2025 Robert D Allen III N/A Sale 27.42K $0.57 $15.63K
Aug 19, 2025 Timothy Edward Lee N/A Sale 29.64K $0.57 $16.90K
Aug 19, 2025 William E Duke N/A Sale 29.64K $0.57 $16.90K
Aug 18, 2025 Jill Andersen N/A Sale 33.35K $0.65 $21.68K
Aug 18, 2025 Julie Green N/A Sale 20.01K $0.65 $13.01K
Aug 18, 2025 Robert D Allen III N/A Sale 18.51K $0.65 $12.03K
Aug 18, 2025 Timothy Edward Lee N/A Sale 20.01K $0.65 $13.01K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 33.09M Mar 31, 2026 11.23% $0.02 1.69%
Perceptive Advisors LLC 20.86M Mar 31, 2026 7.08% $0.53 -4.25%
Bvf Inc 19.53M Mar 31, 2026 6.63% $0.81 0.00%
Maverick Capital Ltd 18.97M Mar 31, 2026 6.44% $0.28 0.00%
Saturn V Capital Management LLC 10.95M Mar 31, 2026 3.72% $2.58 41.55%
Vanguard Group Inc 10.70M Dec 31, 2025 3.63% $0.00 85.74%
Vanguard Capital Management, LLC 10.07M Mar 31, 2026 3.42% $0.00 0.00%
M28 Capital Management LP 9.25M Mar 31, 2026 3.14% $22.35 0.00%
Eventide Asset Management, LLC 9.07M Mar 31, 2026 3.08% $0.20 56.16%
Driehaus Capital Management LLC 8.44M Mar 31, 2026 2.86% $0.08 -35.41%
Soleus Capital Management, L.P. 7.71M Mar 31, 2026 2.62% $0.41 0.00%
State Street Corp 6.94M Mar 31, 2026 2.35% $0.00 23.03%
BlackRock Inc 4.28M Mar 31, 2026 1.45% $0.00 20.72%
Siren, L.L.C. 4.00M Mar 31, 2026 1.36% $0.14 0.00%
ADAR1 Capital Management LLC 3.82M Mar 31, 2026 1.30% $0.29 -1.97%
StemPoint Capital LP 3.75M Mar 31, 2026 1.27% $0.47 278.76%
Adage Capital Partners Gp LLC 3.66M Mar 31, 2026 1.24% $0.01 0.00%
Balyasny Asset Management LLC 3.52M Mar 31, 2026 1.19% $0.01 -7.65%
Millennium Management LLC 3.51M Mar 31, 2026 1.19% $0.00 172.97%
Morgan Stanley - Brokerage Accounts 3.39M Mar 31, 2026 1.15% $0.00 106.80%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Eventide Healthcare & Life Sciences I 9.07M 3.08% ▲ 56.16% Mar 31, 2026
2 Vanguard Total Stock Mkt Idx Inv 7.79M 2.64% ▲ 5.31% Jun 30, 2026
3 iShares Russell 2000 ETF 5.41M 1.83% ▲ 0.60% Jun 30, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 2.43M 0.83% ▲ 2.13% Jun 30, 2026
5 iShares Russell 2000 Value ETF 2.01M 0.68% ▼ 0.69% Jun 30, 2026
6 Russell 2000 Index Non-Lendable Fund 1.40M 0.47% ▲ 0.00% Jun 30, 2026
7 Russell 2000 Equity Index Fund B 1.40M 0.47% ▲ 0.00% Jun 30, 2026
8 Vanguard Russell 2000 ETF 1.22M 0.41% ▲ 0.00% Jun 30, 2026
9 Fidelity Extended Market Index 1.10M 0.37% ▼ 2.50% May 31, 2026
10 MEDICAL BioHealth EUR Acc 1.05M 0.36% ▼ 0.02% May 31, 2026

Financial Highlights

Market Cap: $174.79M
EBITDA: $-81.16M
Book Value: $0.72
Earnings/Share: $-0.29
Profit Margin: -138.90%
Operating Margin: -313.85%
ROA (TTM): -29.59%
ROE (TTM): -60.34%
Revenue (TTM): $55.87M
Revenue/Share (TTM): $0.25
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 21.60%

Valuation Metrics

Enterprise Value: $2.45M
Trailing P/E: 0.00
Forward P/E: 44.64

Shares Statistics

Shares Outstanding: 294.61M
Shares Float: 214.30M
% Insiders: 707.00%
% Institutions: 8,456.20%
Short % Float: 10.99%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$53.43M
Cost of Goods Sold
adjust
$-3.75M
Gross Profit
subtotal
$49.68M
SG&A
adjust
$-66.93M
R&D
adjust
$-38.31M
Operating Income
subtotal
$-55.56M
Other / Non-Operating Items
adjust
$3.07M
Net Income
subtotal
$-52.49M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IVVD.US!